Abstract
7TM receptors constitute one of the largest superfamilies of proteins in the human genome. They are involved in a large number of physiological and pathological processes and thus represent major and important drug targets for the pharmaceutical industry. Although the majority have been deorphanized, many remain orphan and these orphan receptors constitute a large pool of potential drug targets. This review focuses on one of these orphan targets, the Epstein-Barr Virus – induced receptor 2, EBI2 (or GPR183), together with two structurally related receptors, GPR17 and GPR18. The pharmacology and “druggability” of these three receptors are reviewed through a thorough description of their structural and functional properties and in vivo biology together with a status of currently available ligands for these receptors.
Keywords: GPCR, activation mechanism, 7TM receptors, EBI2, GPR18, GPR17, constitutive activity, deorphanization, orphan receptors, druggability, chromosomal region 13q32.3, chemogenomic analysis, pertussis toxin, –, dependent manner, phosphatidylinositol turnover, posttransplant lymphoproliferative diseases
Current Topics in Medicinal Chemistry
Title: EBI2, GPR18, and GPR17 – Three Structurally Related but Biologically Distinct 7TM Receptors
Volume: 11 Issue: 6
Author(s): Kristine Norregaard, Tau Benned-Jensen and Mette Marie Rosenkilde
Affiliation:
Keywords: GPCR, activation mechanism, 7TM receptors, EBI2, GPR18, GPR17, constitutive activity, deorphanization, orphan receptors, druggability, chromosomal region 13q32.3, chemogenomic analysis, pertussis toxin, –, dependent manner, phosphatidylinositol turnover, posttransplant lymphoproliferative diseases
Abstract: 7TM receptors constitute one of the largest superfamilies of proteins in the human genome. They are involved in a large number of physiological and pathological processes and thus represent major and important drug targets for the pharmaceutical industry. Although the majority have been deorphanized, many remain orphan and these orphan receptors constitute a large pool of potential drug targets. This review focuses on one of these orphan targets, the Epstein-Barr Virus – induced receptor 2, EBI2 (or GPR183), together with two structurally related receptors, GPR17 and GPR18. The pharmacology and “druggability” of these three receptors are reviewed through a thorough description of their structural and functional properties and in vivo biology together with a status of currently available ligands for these receptors.
Export Options
About this article
Cite this article as:
Norregaard Kristine, Benned-Jensen Tau and Marie Rosenkilde Mette, EBI2, GPR18, and GPR17 – Three Structurally Related but Biologically Distinct 7TM Receptors, Current Topics in Medicinal Chemistry 2011; 11 (6) . https://dx.doi.org/10.2174/1568026611109060618
DOI https://dx.doi.org/10.2174/1568026611109060618 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adenoviral Vector-Mediated Gene Transfer for Human Gene Therapy
Current Gene Therapy Radiolabeled Imaging Probes Targeting Angiogenesis for Personalized Medicine
Current Pharmaceutical Design Engineered Biosynthesis of Medicinally Important Plant Natural Products in Microorganisms
Current Topics in Medicinal Chemistry Phage Display Derived Therapeutic Antibodies
Current Pharmaceutical Biotechnology Radiolabeled Compounds in the Development of Cytotoxic Agents
Current Pharmaceutical Design Targeting the Secretory Pathway for Anti-Inflammatory Drug Development
Current Topics in Medicinal Chemistry Anti-proliferative Properties of miR-20b and miR-363 from the miR-106a-363 Cluster on Human Carcinoma Cells
MicroRNA Histone Deacetylase Inhibitors in Cancer Therapy: New Compounds and Clinical Update of Benzamide-Type Agents
Current Topics in Medicinal Chemistry JAK/STAT Signal Transduction: Promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases
Current Drug Targets Minor-Groove Binding Agents: Rational Design of Carboxamide Bond Isosteres
Current Topics in Medicinal Chemistry New Direct and Frontal Tissue Acquisition Tools for Gene Expression Analysis in Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Laboratory Techniques for Human Viral Encephalitis Diagnosis
Infectious Disorders - Drug Targets Recent Patents on Peptide Self-Assembled Hydrogels as Nanostructured Biomaterials
Recent Patents on Nanomedicine Signal Transduction Therapy for Cancer - Whither Now?
Current Signal Transduction Therapy Tyrosine Kinase Inhibitors (TKIs) in Lung Cancer Treatment: A Comprehensive Analysis
Current Cancer Drug Targets Nanoparticle Therapy for Prostate Cancer: Overview and Perspectives
Current Topics in Medicinal Chemistry Genistein Down-Regulates miR-223 Expression in Pancreatic Cancer Cells
Current Drug Targets 3D QSAR Pharmacophore Modeling for c-Met Kinase Inhibitors
Medicinal Chemistry A Review on Natural Sources Derived Protein Nanoparticles as Anticancer Agents
Current Topics in Medicinal Chemistry Studies on Anticancer Activities of Lactoferrin and Lactoferricin
Current Protein & Peptide Science